Market closedNon-fractional

IGM Biosciences/IGMS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Ticker

IGMS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Mountain View, United States

Employees

216
Website
igmbio.com

IGM Biosciences Metrics

BasicAdvanced
$381M
Market cap
-
P/E ratio
-$4.21
EPS
0.22
Beta
-
Dividend rate
$381M
0.22
7.982
7.769
21.271
25.381
-37.57%
-118.26%
172.28
2.36
2.36
-1.864
32.31%
-18.49%
11.60%

What the Analysts think about IGM Biosciences

Analyst Ratings

Majority rating from 10 analysts.
Buy

IGM Biosciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12,450.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$400K
-33.33%
Net income
-$50M
-17.82%
Profit margin
-12,450.00%
23.27%

IGM Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.16%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.43
-$1.04
-$1.01
-$0.83
-
Expected
-$1.43
-$1.21
-$1.03
-$0.83
-$0.04
Surprise
-0.28%
-14.26%
-2.19%
-0.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for IGM Biosciences stock?

IGM Biosciences (IGMS) has a market cap of $381M as of July 06, 2024.

What is the P/E ratio for IGM Biosciences stock?

The price to earnings (P/E) ratio for IGM Biosciences (IGMS) stock is 0 as of July 06, 2024.

Does IGM Biosciences stock pay dividends?

No, IGM Biosciences (IGMS) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next IGM Biosciences dividend payment date?

IGM Biosciences (IGMS) stock does not pay dividends to its shareholders.

What is the beta indicator for IGM Biosciences?

IGM Biosciences (IGMS) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell IGM Biosciences stock

Buy or sell IGM Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing